Preliminary data were announced from 2 clinical trials evaluating Arexvy in a broader population of adults at increased for RSV disease.

AbbVie is reaching for the Sky(rizi) as it spent a staggering $51.5 million on TV drug ads for its immunology blockbuster in October. | AbbVie is reaching for the Sky(rizi) as it spent a staggering ...

Kroger will begin phasing out their printed ads in certain markets, including those in Michigan, Indiana, Mississippi and Oregon, this May. Customers will only be able to access print ads by going ...

GSK announced on Tuesday that a single dose of its Arexvy vaccine against respiratory syncytial virus (RSV) was 43.3% effective in preventing severe illness three years after patients 60 and older ...

Pharmaceutical giant GSK has won a key part of the regulatory approval needed to roll out its vaccine for respiratory syncytial virus (RSV) to adults aged 50 to 59. The US Food and Drug ...

PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced new preliminary data for AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) in adults aged 18-49 at increased risk for ...

Based on data from its AReSVi-006 trial, the British vaccine maker said Arexvy, compared to a placebo, led to an overall ...

Print ads that run in local or national, daily or weekly news publications Newspaper advertising has been around longer than any other form of advertising we see today and is still the first kind ...

GSK (GSK) announced new preliminary data for AREXVY in adults aged 18-49 at increased risk for lower respiratory tract disease, LRTD, caused by respiratory syncytial virus due to certain ...

Specifically, the FDA recently approved Arexvy, the world’s first vaccine to fight RSV in adults aged 60 and older. According to its manufacturer GSK, the single shot provides long-term ...

Drugmaker GSK saw a sharp drop in revenue from its blockbuster Arexvy vaccine in the third quarter, dampening overall sales growth. Sales of the jab for respiratory syncytial virus (RSV ...

GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation unjustified, leading to a "Strong Buy" rating. The company’s diversified ...